Publication|Articles|November 18, 2026

Oncology

  • ONCOLOGY Vol 40, Issue 8
  • Volume 40
  • Issue 8
  • Pages: 256-259

3 Patient Profiles: ADC Therapy in TNBC

Explore 3 clinical cases illustrating first-line and postneoadjuvant ADC selection, toxicity considerations, and strategies to address clinical trial access barriers in patients with TNBC.

LEARNING OBJECTIVES

Upon successful completion of this activity, you should be better prepared to:

• Assess current standards of care and unmet needs for treating early-stage triple-negative breast cancer (TNBC)

• Describe the emerging role of antibody-drug conjugates in early-stage TNBC and potential practice implications of ongoing clinical trials

• Recognize key drivers of disparities in treatment outcomes, including access to biomarker testing, novel therapies, and clinical trials

• Enhance patient communication around treatment options, including treatment expectations, toxicity management, and shared decision-making

• Incorporate best practices for PD-L1 testing and interpretation to guide immunotherapy decisions in metastatic TNBC

• Implement treatment sequencing approaches for patients with metastatic TNBC across the disease continuum

• Apply evidence-based strategies for multidisciplinary collaboration in managing adverse effects and ensuring continuity of care across settings

RELEASE DATE: October 7, 2026

EXPIRATION DATE: October 7, 2027

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off-label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.

INSTRUCTIONS FOR PARTICIPATION and HOW TO RECEIVE CREDIT

1. Read this activity in its entirety.

2. Go to https://gotoper.com/oncobytes-tnbc-1-postref to access and complete the posttest.

3. Answer the evaluation questions.

4. Request credit using the drop-down menu.

YOU MAY IMMEDIATELY DOWNLOAD YOUR CERTIFICATE.

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. For advanced disease that expresses PD-L1 (combined positive score [CPS] ≥ 10), first-line chemotherapy plus a PD-1/PD-L1 inhibitor improved survival in KEYNOTE-355 (NCT02819518), but median progression-free survival (PFS) was still under 10 months.1 In 2026, the FDA approved 2 TROP2-directed antibody-drug conjugates (ADC) for first-line unresectable locally advanced or metastatic TNBC: datopotamab deruxtecan (Dato-DXd) for patients who are not candidates for PD-1/PD-L1 inhibitor therapy,2 and sacituzumab govitecan (SG) as a single agent for that population and with pembrolizumab for CPS ≥ 10 disease.3 ADCs are also being tested in early-stage disease, and access shapes who benefits from them.

Case 1. A 50-year-old patient presents with TNBC metastatic to the lung, pleura, and peritoneum. PD-L1 CPS is 50; germline BRCA1/2 is wild type.

SG plus pembrolizumab is a valid first-line option for this patient. A CPS of 50 is well above the CPS ≥ 10 threshold for pembrolizumab-based first-line therapy.1,3 Because the patient has lung and pleural disease, the interstitial lung disease (ILD) profile of each ADC is also relevant. SG’s prescribing information carries no warning or precaution for ILD, though ILD accounted for permanent discontinuation in 1.1% of patients in ASCENT-03 (NCT05382299).4 The Dato-DXd prescribing information carries warnings for ILD/pneumonitis and ocular adverse reactions.5 In TROPION-Breast02 (NCT05374512), ILD/pneumonitis led to permanent discontinuation in 0.9% of patients and was fatal in 1 patient (0.3%).5

The case for SG plus pembrolizumab rests on ASCENT-04/KEYNOTE-D19 (NCT05382286), a phase 3 trial that randomly assigned 443 patients with previously untreated PD-L1–positive (CPS ≥ 10) advanced TNBC to SG plus pembrolizumab (n = 221) or chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin) plus pembrolizumab (n = 222).6 Median PFS was 11.2 vs 7.8 months (HR, 0.65; 95% CI, 0.51-0.84; P < .001). At the primary analysis, overall survival (OS) was immature (26% of patients died; median not reached in either arm). Crossover was built in, and 81% of control-arm patients who received subsequent therapy received SG.6 In a subsequent analysis at the same median follow-up (14.0 months), PFS after the next line of therapy (PFS2) favored SG plus pembrolizumab despite crossover (HR, 0.67; 95% CI, 0.48-0.95).7 Grade 3 or higher adverse effects were similar (71% vs 70%), but treatment discontinuation was less frequent with SG plus pembrolizumab (12% vs 31%).6 The result is a clear PFS benefit. A survival benefit has not been demonstrated.

ASCENT-04 is one of 3 phase 3 trials of TROP2-directed ADCs in first-line metastatic TNBC that have met their primary end points (Table 1).2-9 The other 2 enrolled patients who were not candidates for PD-1/PD-L1 inhibitors, and cross-trial comparisons are not appropriate.8,9 National Comprehensive Cancer Network guidelines now list SG plus pembrolizumab as a category 1, preferred first-line option for CPS ≥ 10 disease.10 For patients with CPS < 10 disease, or who are otherwise not candidates for PD-1/PD-L1 inhibitor therapy, SG and Dato-DXd are category 1, preferred options in the absence of a germline BRCA1/2 pathogenic variant.10 Two phase 3 first-line trials have yet to report: TROPION-Breast05 (NCT06103864), testing Dato-DXd with or without durvalumab against chemotherapy plus pembrolizumab in the same PD-L1–positive population,11 and TroFuse-011 (NCT06841354), testing sacituzumab tirumotecan (sac-TMT) alone or with pembrolizumab vs chemotherapy in patients with PD-L1 CPS < 10.12,13

Case 2. A 36-year-old premenopausal woman with stage II (cT2N1) TNBC receives neoadjuvant chemoimmunotherapy per the KEYNOTE-522 regimen. Surgical pathology shows residual invasive disease in the breast and 1 axillary lymph node (ypT1N1). Germline BRCA1/2 testing is negative.

Residual invasive disease after neoadjuvant therapy marks a high risk of recurrence: in KEYNOTE-522 (NCT03036488), 33.1% of pembrolizumab-treated patients without a pathologic complete response (pCR) had an event at a median follow-up of 39.1 months vs 5.5% of those with a pCR.14 Pembrolizumab reduced events across most residual cancer burden categories, but risk with residual disease remains high,15 and the current adjuvant options are capecitabine, established in CREATE-X (UMIN000000843),16 and pembrolizumab continued from the neoadjuvant regimen.14,17 That risk makes early consideration of a postneoadjuvant ADC trial appropriate.

These regimens are the comparator arms of 3 phase 3 trials in this population, each with invasive disease–free survival as the primary end point: TROPION-Breast03 (NCT05629585; Dato-DXd with or without durvalumab vs capecitabine and/or pembrolizumab; N = 1174, accrual complete),18,19 ASCENT-05/OptimICE-RD (NCT05633654; SG plus pembrolizumab vs pembrolizumab with or without capecitabine; N ≈ 1514),20 and TroFuse-012 (NCT06393374; sac-TMT plus pembrolizumab vs pembrolizumab with or without capecitabine; N ≈ 1530).21 Each requires residual invasive disease after protocol-specified neoadjuvant therapy, and all 3 exclude patients with a germline BRCA1/2 mutation,19-21 for whom adjuvant olaparib is recommended.10 None has yet reported results, and no signal yet suggests that one ADC or one immunotherapy combination outperforms another. In practice, the trial open at the patient’s site may be the deciding factor.

Because treatment is intended to be curative, the threshold for acceptable ADC toxicity is lower than in the metastatic setting, and the choice of trial can be matched to the patient’s tolerance of the KEYNOTE-522 regimen. After immune-related adverse effects, an immunotherapy-free arm may be preferable. With SG, the prescribing information directs prophylactic granulocyte colony-stimulating factor and prompt antidiarrheal therapy.4 Before Dato-DXd, the prescribing information requires an ophthalmic examination at initiation and every 3 cycles, and patients should be counseled to report new or worsening respiratory symptoms.5 Other early-stage trials are testing ADCs and novel combinations in different populations (Table 2).22-24

Case 3. A 44-year-old Latina patient has residual disease (ypT1N1) after neoadjuvant chemotherapy for stage II TNBC. Germline BRCA1/2 testing is negative, and PD-L1 CPS is 8. Her oncologist is unsure whether to refer her for adjuvant therapy or a clinical trial. She lives 2 hours from the nearest academic center and speaks primarily Spanish.

The growing number of ADC trials makes trial access part of treatment planning, not an afterthought. This patient may well be eligible for the postneoadjuvant trials above, but the conversation belongs at diagnosis, while neoadjuvant treatment is underway, so the possibility of a trial is planted before residual disease is confirmed. Black patients were underrepresented in the pivotal trials: approximately 4.8% in the pembrolizumab-chemotherapy arm of KEYNOTE-522 and 4% in TROPION-Breast02,25 whose investigators noted that continued efforts are needed.9 In a cross-sectional study of 1150 patients with breast cancer, the likelihood of discussing or enrolling in a trial when one was offered did not differ significantly across racial and ethnic groups after adjustment.26 Time commitment was among the barriers reported.26

The barriers in this case have practical responses. Referrals can go to community sites that run the same trials, not only to the academic center, with decentralized elements such as remote monitoring and local laboratory draws. Travel, childcare, and co-pay assistance programs reduce the cost burden. Translated consent forms and patient-facing materials, interpreters, bilingual coordinators, and clinical trial navigators address the language barrier. Transparency from the start about cost and time commitment lets her decide on her own terms. Up-front biomarker testing helps preserve treatment options if disease progresses. Other common barriers include out-of-pocket and indirect costs, insurance gaps, historical mistrust, lack of diverse research staff, restrictive eligibility criteria, and trials concentrated at academic centers.

In TNBC, TROP2-directed ADCs have moved into the first-line metastatic setting and are being tested after neoadjuvant therapy. The practical implications follow from the 3 cases: match first-line therapy to PD-L1 status and toxicity considerations, raise the possibility of a postneoadjuvant trial before residual disease is confirmed, and address logistical barriers before they exclude a patient from a trial.

Key References

6. Tolaney SM, de Azambuja E, Kalinsky K, et al; ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N Engl J Med. 2026;394(4):354-366. doi:10.1056/NEJMoa2508959

19. Bardia A, Pusztai L, Albain K, et al. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024;16:17588359241248336. doi:10.1177/17588359241248336

26. Chen N, Freeman JQ, Zhao F, et al. Clinical trial discussion and participation in a breast cancer cohort by race and ethnicity. JAMA Netw Open. 2025;8(6):e2515205. doi:10.1001/jamanetworkopen.2025.15205

For FULL References List, visit
https://www.gotoper.com/oncobytes-tnbc-1-postref

CME Posttest Questions

1) You are referred a patient with a recent diagnosis of metastatic triple-negative breast cancer (TNBC). HER2 expression is 1+ by immunohistochemistry. PD-L1 combined positive score is 15. According to recent clinical trial evidence, which of the following treatment approaches would be most appropriate for this patient?

A. Paclitaxel plus carboplatin

B. Paclitaxel plus carboplatin plus pembrolizumab

C. Sacituzumab govitecan or datopotamab deruxtecan

D. Sacituzumab govitecan plus pembrolizumab

E. Trastuzumab deruxtecan plus pertuzumab

2) RS is a 63-year-old African American woman with metastatic TNBC. She began working as a teenager to support her family and did not complete high school. During her clinic appointment discussing treatment options, she voices concerns about making the right choice. Which of the following is an evidence-based strategy for overcoming barriers to clinical trial access for underrepresented patient populations such as RS?

A. Referring patients to large cancer centers for clinical trials

B. Following up by phone to explain the importance of clinical trials

C. Providing patients with access to scientific literature supporting the need for a clinical trial

D. Using patient navigators to provide culturally relevant, targeted education about clinical trials

3) Which of the following pretreatment evaluations is required before initiating datopotamab deruxtecan in a curative-intent, early-stage TNBC trial, given its toxicity profile?

A. Baseline echocardiogram and thyroid function testing

B. Baseline ophthalmic examination and pulmonary function testing

C. Baseline renal ultrasound and urinalysis

D. Baseline skeletal survey and bone density scan

Claim Your CME Credit at https://www.gotoper.com/oncobytes-tnbc-1-postref

To learn more about this topic, including information on PD-L1 testing best practices, treatment sequencing in metastatic TNBC, and early-stage ADC data from relevant trials, go to https://www.gotoper.com/oncobytes-tnbc-1-activity

CME Provider Contact Information

Physicians’ Education Resource®, LLC
259 Prospect Plains Road, Building H
Cranbury, NJ 08512
onc-info@gotoper.com


Related to this article